ReportsandReports.com
adds report “Human Insulin Market by Product Type (Human Insulin (Short Acting,
Intermediate Acting, Premixed), Modern Human Insulin (Rapid Acting, Long
Acting, Premixed), by Brand (Lantus, Apidra, Levemir, NovoRapid, Novomix,
Tresiba, Others) - Forecast to 2018” to its store.
Several
initiatives and healthcare reforms have been developed in order to support the
adoption of human insulin among diabetic population as diabetes will be the
seventh leading cause of mortality by 2030. WHO and IDF began joint initiative
to reduce the impact of diabetes and related chronic conditions on the health
of children and adults worldwide. Apart from this, the U.S. government has now
started taking various initiatives to boost its biosimilars market. In 2013,
Obama’s administration sponsored a budget of $4.5 billion, an increase of 17%
over 2012, to FDA in order to support the review of generics and biosimilars.
The funding would mostly come from user fees paid by drug makers. More than
$364 million will be allocated to support generic drug activities and
development of biosimilars, out of which $20 million will be allocated to the
FDA for biosimilars.
Companies mentioned in this report “Human Insulin Market by Product Type (Human Insulin (Short Acting,
Intermediate Acting, Premixed), Modern Human Insulin (Rapid Acting, Long
Acting, Premixed), by Brand (Lantus, Apidra, Levemir, NovoRapid, Novomix,
Tresiba, Others) - Forecast to 2018”:-
·
Novo
Nordisk
·
EliLilly
·
Sanofi
Aventis
·
Biocon
·
Julphar
Pharmaceuticals
Modern human insulin accounted for the largest share -84%- of global
human insulin market. Premixed modern human insulin and long acting human
insulin are estimated to grow at a brisk pace over the next five years. The
high growth in these segments can be attributed to the growing demand of
Apidra, Lantus, and Levemir. Furthermore, these drugs reported high efficiency
and effectiveness as compared to other synthetic insulin, animal insulin, and
other human insulin.
New technologies such as safety pen needles and infusion pumps have
emerged as efficient mode of delivery for human insulin. Pen needles offer
significant benefits to the healthcare sector. The usage of easy to fit needles
is rising due to the convenience offered by them. These needles are easy to
attach, remove, and dispose, thus they can be easily used by patients with
manual dexterity problems, and visual impairment. Diabetes educators and
clinicians across the world recommend the usage of needles with shorter lengths
and higher gauge sizes for convenience and to minimize pain. Owing to these
factors, technological advancement is expected to be a major revenue pocket for
the human insulin market in the coming years.
Countries such as China, India, Japan, and Korea will also offer
potential growth opportunities to human insulin market. Of all the countries,
China is estimated to be the fastest growing market for human insulin market.
Saudi Arabia, Qatar, Egypt, U.A.E, and Brazil will also emerge as lucrative
markets for human insulin market.
Request a sample
copy of this report @ http://www.reportsnreports.com/contacts/requestsample.aspx?name=291200
.
Above all, most of the early biologic human insulin lost their patent
protection in the first half of the 20th century, while many of the current
best-selling drugs such as insulin glargine, insulin as part, and insulin
lispro are all set to lose their patent protection in the coming years. This
creates new opportunities for biosimilar drugs which is estimated to grow at a
CAGR of 35% from 2014-2019.
The grey area while estimating the market size is the variable price
of human insulin across the globe as it differs widely across each country.
From an insight perspective, this research report focuses on the
qualitative data, market size, share, and growth of various segments and
sub-segments, competitive landscape, and company profiles.
The qualitative data covers various levels of industry analysis, such
as market dynamics (drivers, restraints, opportunities, and threats), and
porter’s five forces analysis at global level. The report also offers market
shares, sizes, and related growth of various segments in the industry. It also
focuses on the emerging and high-growth segments of human insulin market
(Biosimilars of human insulin, long acting human insulin, and premixed human
insulin), high-growth regions (Asia-Pacific), and the initiatives of their
respective governments.
The competitive landscape covers the growth strategies adopted by
industry players in the last three years. The company profiles comprise the
basic views on the key players in the human insulin market and the product
portfolios, developments, and strategies adopted by market players to maintain
and increase their market shares in the near future. The above-mentioned market
research data, current market size, and forecast of future trends will help the
key players and new entrants to make the necessary decisions regarding product
offerings, geographic focus, change in strategic approach, R&D investments
for innovations in products and technologies, and levels of output in order to
remain successful.
Purchase a copy
of this report @ http://www.reportsnreports.com/purchase.aspx?name=291200
.
About Us:
ReportsandReports.com is your single source for all market
research needs. Our database includes 450,000+ market research reports from
over 95 leading global publishers & in-depth market research studies of
over 5000 micro markets. We offer you customization options on reports by &
custom reports through MarketsandMarkets.com. With comprehensive information
about the publishers and the industries for which they publish market research
reports, we help you in your purchase decision by mapping your information
needs with our huge collection of reports.
No comments:
Post a Comment
Note: only a member of this blog may post a comment.